Infection and Drug Resistance

Scope & Guideline

Advancing the fight against infections and drug resistance.

Introduction

Welcome to the Infection and Drug Resistance information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of Infection and Drug Resistance, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1178-6973
PublisherDOVE MEDICAL PRESS LTD
Support Open AccessYes
CountryNew Zealand
TypeJournal
Convergefrom 2009 to 2024
AbbreviationINFECT DRUG RESIST / Infect. Drug Resistance
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressPO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND

Aims and Scopes

The journal 'Infection and Drug Resistance' focuses on the critical intersection of infectious diseases and antimicrobial resistance, providing a platform for research that contributes to the understanding, prevention, and treatment of infections. The journal emphasizes the need for innovative approaches in combating drug-resistant pathogens, aligning with contemporary global health challenges.
  1. Antimicrobial Resistance Mechanisms:
    Research on the genetic and phenotypic mechanisms of antimicrobial resistance in various pathogens, including bacteria, fungi, and viruses, is a primary focus, aiming to elucidate the pathways through which resistance develops and spreads.
  2. Infectious Disease Epidemiology:
    The journal publishes studies that analyze the epidemiological trends of infectious diseases, including their transmission dynamics, risk factors, and the impact of social and environmental determinants on disease outbreaks.
  3. Clinical Outcomes and Treatment Strategies:
    Articles explore clinical outcomes associated with different treatment regimens for infections, particularly those caused by multidrug-resistant organisms, and evaluate the efficacy and safety of novel therapeutic agents.
  4. Diagnostic Innovations:
    There is a strong focus on the development and validation of new diagnostic methods, including molecular techniques such as metagenomic next-generation sequencing, aimed at improving the speed and accuracy of pathogen identification.
  5. Public Health Interventions:
    The journal highlights studies on public health interventions and strategies for infection prevention and control, particularly in healthcare settings, to mitigate the impact of drug-resistant infections.
  6. Global Health Perspectives:
    Research articles often incorporate global health perspectives, addressing the challenges of infectious diseases and antimicrobial resistance in various geographical and socio-economic contexts.
The journal has seen a notable evolution in its focus areas, reflecting current global health challenges and emerging scientific advancements. This section outlines the new trends and topics that are increasingly becoming central to the journal's publications.
  1. Metagenomic Approaches:
    There is a rising trend in the application of metagenomic next-generation sequencing for diagnosing complex infections, allowing for a more comprehensive understanding of microbial communities and resistance profiles.
  2. Machine Learning and AI in Infectious Diseases:
    The integration of machine learning and artificial intelligence in predicting infection outcomes and resistance patterns is gaining traction, with studies exploring how these technologies can enhance clinical decision-making.
  3. Impact of COVID-19 on Other Infections:
    Research examining the impact of the COVID-19 pandemic on the epidemiology and management of other infectious diseases, including the resurgence of previously controlled infections, is increasingly relevant.
  4. Vaccination Strategies and Acceptance:
    With the ongoing vaccination efforts against COVID-19 and other infectious diseases, research on vaccine uptake, acceptance, and the associated factors is becoming a significant focus area.
  5. One Health Approach:
    The journal is increasingly publishing articles that adopt a One Health perspective, addressing the interconnectedness of human, animal, and environmental health in the context of infectious diseases and antimicrobial resistance.
  6. Public Health Strategies for Infection Control:
    There is a growing emphasis on evaluating and developing public health strategies and interventions for infection prevention and control, particularly in healthcare settings and during outbreaks.

Declining or Waning

While 'Infection and Drug Resistance' has maintained a robust focus on antimicrobial resistance and infectious diseases, certain areas of research have seen a decline in publication frequency or relevance. These waning scopes highlight shifts in research priorities or emerging challenges that may overshadow previously popular topics.
  1. Traditional Antibiotic Approaches:
    Research focusing solely on conventional antibiotic therapies without considering resistance mechanisms or the need for combination therapies has declined as the field shifts towards more integrated approaches to combat resistance.
  2. Single-Agent Studies:
    Studies evaluating the efficacy of single-agent antibiotic therapies have become less frequent as the understanding of polymicrobial infections and the need for combination therapies gains prominence.
  3. Basic Laboratory Research:
    There is a noticeable decline in purely basic laboratory studies that do not translate into clinical relevance or application, as the journal increasingly prioritizes translational research with direct implications for patient care.
  4. Historical Epidemiological Data:
    Research that focuses solely on historical epidemiological data without providing insights into current trends or implications for practice appears to be waning, reflecting a shift towards real-time data analysis and its application in public health.

Similar Journals

Gut Pathogens

Advancing Knowledge in Gut Microbiota and Pathogens
Publisher: BMCISSN: 1757-4749Frequency: 1 issue/year

Gut Pathogens, published by BMC in the United Kingdom, is a premier open-access journal focusing on the intersection of gut health and infectious diseases. With its impact firmly established since its inception in 2009, the journal has earned impressive rankings, including Q1 in renowned categories such as Gastroenterology, Infectious Diseases, Microbiology, and Parasitology, while maintaining a strong presence in Virology. The journal serves as a vital resource for researchers, professionals, and students interested in the intricate relationships between gut microbiota and pathogenic organisms, offering insights that drive advancements in treatment and prevention strategies. By providing unrestricted access to high-quality research, Gut Pathogens fosters a collaborative environment, encouraging the dissemination of knowledge and innovation within the field. The journal publishes original research, reviews, and case studies, all designed to address contemporary challenges in gut health, ultimately aiming to improve patient outcomes and public health worldwide.

Mediterranean Journal of Infection Microbes and Antimicrobials

Bridging gaps in understanding infectious diseases.
Publisher: GALENOS PUBL HOUSEISSN: 2147-673XFrequency: 1 issue/year

Mediterranean Journal of Infection Microbes and Antimicrobials is a distinguished open-access journal published by GALENOS PUBL HOUSE, dedicated to advancing the understanding of infectious diseases and microbiology. Since its inception in 2011, this journal has been a vital resource for researchers, professionals, and students interested in the intricate world of microbes and their impacts on human health. With its ISSN 2147-673X, the journal has progressively gained visibility, although it currently holds a Q4 ranking in multiple categories including Immunology and Microbiology, and Infectious Diseases for the year 2023. The journal operates from its headquarters in Istanbul, Turkey, and features a rich array of articles that contribute to the field’s body of knowledge. As a platform enhancing the accessibility of research, it invites submissions from global contributors to foster collaboration and innovation in tackling microbial challenges.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Championing open access to vital scientific insights.
Publisher: ELSEVIER TAIWANISSN: 1684-1182Frequency: 6 issues/year

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

Revista Espanola de Quimioterapia

Bridging Research and Practice in Medicinal Chemistry
Publisher: SOCIEDAD ESPANOLA QUIMIOTERAPIAISSN: 0214-3429Frequency: 6 issues/year

The Revista Espanola de Quimioterapia, published by the SOCIEDAD ESPANOLA QUIMIOTERAPIA, is a pivotal open-access journal that has been advancing the field of clinical microbiology and pharmacology since its inception in 1989. With an E-ISSN of 1988-9518, this journal caters to a diverse audience of researchers, healthcare professionals, and students, providing them with critical insights into the latest developments in medicinal chemistry and therapeutic strategies. Located in Madrid, Spain, the journal reflects the rigorous academic standards of its associated institutions, contributing significantly to the translation of research into clinical practice. Achieving a Q3 ranking in the fields of Medicine, Microbiology, and Pharmacology in 2023 attests to its growing influence and relevance in the scientific community, making it a vital resource for those engaged in the quest for innovative solutions to pressing healthcare challenges. The journal prides itself on its commitment to maintaining an open-access model since 2018, ensuring that vital research is freely accessible to foster greater knowledge sharing and collaboration within the global scientific community.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Transforming Knowledge into Action Against Infections
Publisher: ELSEVIER SCIENCE INCISSN: 0732-8893Frequency: 12 issues/year

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, published by Elsevier Science Inc, is a leading journal in the fields of Infectious Diseases, Microbiology, and Medicine. Since its inception in 1983, this esteemed journal has consistently provided a platform for original research and comprehensive reviews that advance the understanding of diagnostic microbiology and its implications for infectious diseases. With an impressive impact factor placing it in the Q2 category in multiple relevant fields as of 2023, it stands out with Scopus rankings reinforcing its significance in academia, ranking #136 out of 344 in Infectious Diseases and #64 out of 140 in Medical Microbiology. This journal is essential for researchers, healthcare professionals, and students who seek to stay abreast of the latest developments and trends in infectious diagnostics. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE is committed to fostering excellence in research quality and academic rigor, ensuring accessibility to vital knowledge for addressing some of the most pressing health challenges of our time.

Pathogens

Advancing the Frontiers of Infectious Disease Research
Publisher: MDPIISSN: Frequency: 12 issues/year

Pathogens is a leading open-access journal published by MDPI since 2012, dedicated to advancing the understanding of infectious agents and their interactions with hosts in the fields of immunology, microbiology, and molecular biology. Based in Switzerland, this journal plays a crucial role in disseminating high-quality research that spans from fundamental studies of pathogen biology to the implications for global health and disease management. With a commendable impact factor and prestigious Q2 rankings across multiple categories—including Immunology and Microbiology—Pathogens ensures visibility and accessibility for groundbreaking findings. The journal embraces the ethos of open access, allowing researchers, professionals, and students to access critical research anytime, facilitating a collaborative and innovative academic environment. By bridging the gap between research and application, Pathogens is instrumental in shaping the future of infectious disease research and management.

Expert Review of Anti-Infective Therapy

Elevating Standards in Anti-Infective Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-7210Frequency: 12 issues/year

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

JOURNAL OF CHEMOTHERAPY

Elevating Standards in Chemotherapy Research
Publisher: TAYLOR & FRANCIS LTDISSN: 1120-009XFrequency: 6 issues/year

Journal of Chemotherapy is a distinguished peer-reviewed academic journal published by Taylor & Francis Ltd, focusing on the dynamic fields of infectious diseases, oncology, and pharmacology. With its ISSN 1120-009X and E-ISSN 1973-9478, this journal has been at the forefront of chemotherapy research since its inception in 1989 and continues to play a vital role in advancing medical science through rigorous studies and reviews. It currently holds a respectable position in various Scopus categories, ranked Q3 in several important disciplines, reflecting its commitment to providing quality research. Although it operates under a subscription model, Journal of Chemotherapy remains a crucial resource for practitioners and academics alike, facilitating knowledge exchange and innovation in the treatment of diseases through chemotherapy. With access to the latest findings and therapeutic advancements, this journal is a must-read for researchers, medical professionals, and students seeking to enhance their understanding of emerging trends in chemotherapy.

ACS Infectious Diseases

Elevating Research to Combat Infectious Threats
Publisher: AMER CHEMICAL SOCISSN: 2373-8227Frequency: 12 issues/year

ACS Infectious Diseases is a premier journal in the field of infectious diseases, published by the American Chemical Society. With an impressive Impact Factor that places it in the Q1 category for Infectious Diseases in 2023, the journal serves as an essential resource for researchers, healthcare professionals, and students dedicated to the study of infectious agents and their impact on public health. Established in 2015, the journal is committed to publishing cutting-edge research that enhances our understanding of infectious diseases and fosters the development of innovative interventions. Although not an open access journal, it provides a platform for high-quality research that influences policies and practices in the field. With an address located at 1155 16TH ST, NW, WASHINGTON, DC 20036, ACS Infectious Diseases is an authoritative voice in advancing the science and practice of infectious disease management.

Infection and Chemotherapy

Exploring Innovations in Infectious Disease Treatment
Publisher: KOREAN SOC ANTIMICROBIAL THERAPYISSN: 2093-2340Frequency: 4 issues/year

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.